Scynexis (SCYX) EBITDA Margin (2013 - 2026)
Scynexis' (SCYX) quarterly EBITDA Margin came in at 56.42% in Q4 2025, up 88068.0% YoY from N/an in Q4 2024, and up 102.24% on a QoQ basis from 2516.47% in Q3 2025.
Scynexis (SCYX) EBITDA Margin (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 12 years of EBITDA Margin data on file, last reported at 56.42% in Q4 2025.
- Quarterly EBITDA Margin rose 88068.0% year-over-year to 56.42% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 119.86% (up 125733.0% YoY) and the FY2025 annual result came in at 78.03%, up 91282.0% from the prior year.
- EBITDA Margin rose to 56.42% in Q4 2025, from 2516.47% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 88.63% in Q2 2023 to a low of 3767.64% in Q3 2021.
- A 5-year average of 1448.86% and a median of 1255.03% in 2024 frame the typical range for EBITDA Margin.
- The widest YoY moves for EBITDA Margin: up 236744 bps in 2022, down 280649 bps in 2022.
- Tracing SCYX's EBITDA Margin over 5 years: stood at 3734.84% in 2021, then jumped by 61 bps to 1475.13% in 2022, then soared by 73 bps to 397.88% in 2023, then plunged by 107 bps to 824.26% in 2024, then surged by 107 bps to 56.42% in 2025.
- The last three EBITDA Margin figures came in at 56.42% (Q4 2025), 2516.47% (Q3 2025), and 700.95% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - | -3,308.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,308.51% |
| Dec 31, 2025 | 56.42% |
| Sep 30, 2025 | -2,516.47% |
| Jun 30, 2025 | -700.95% |
| Mar 31, 2025 | -3,350.19% |
| Dec 31, 2024 | -824.26% |
| Sep 30, 2024 | -1,563.64% |
| Jun 30, 2024 | -1,255.03% |
| Mar 31, 2024 | -692.50% |
| Dec 31, 2023 | -397.88% |
| Sep 30, 2023 | -573.42% |
| Jun 30, 2023 | 88.63% |
| Mar 31, 2023 | -945.31% |
| Dec 31, 2022 | -1,475.13% |
| Sep 30, 2022 | -1,400.19% |
| Jun 30, 2022 | -1,643.08% |
| Mar 31, 2022 | -2,819.71% |
| Dec 31, 2021 | -3,734.84% |
| Sep 30, 2021 | -3,767.64% |
| Mar 31, 2021 | -13.23% |